Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $50 price target on Ventyx Biosciences. The stock remains the firm’s top pick for 2023 and after its R&D day, Piper is more bullish for several reasons. The firm said the company is said to be catalyst rich in 2023, and dosing details were provided for the psoriasis, Crohn’s, and PSA trials that are expected to achieve efficacy similar to biologics.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTYX:
- Ventyx Biosciences price target raised to $65 from $50 at Evercore ISI
- Ventyx Biosciences announces pipeline updates, strategic priorities
- Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day
- Ventyx Biosciences management to meet with Piper Sandler
- Ventyx Biosciences appoints Allison Hulme, Ph.D. to board
